Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study Regarding the Incidence of Anti-platelet Factor 4-antibodies in Patients Aged 18 to 60 Years With Spontaneous or Infection- or Vaccine-associated or Recurrent Venous and/or Arterial Thrombosis
Sponsor: Cardioangiologisches Centrum Bethanien
Summary
Prospective investigation of the incidence of anti-platelet factor 4 antibodies in suspected immune-associated arterial and/or venous thrombosis
Official title: The APIT Study: Prospective Observational Study of the Incidence of Anti-platelet Factor 4 Antibodies in Suspected Immune-associated Arterial and/or Venous Thrombosis
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
OBSERVATIONAL
Enrollment
200
Start Date
2024-07-01
Completion Date
2027-01
Last Updated
2024-10-21
Healthy Volunteers
No
Conditions
Interventions
Determination of anti-platelet factor 4 antibodies in the blood
The anti-platelet factor 4 antibodies in the blood are determined using latex agglutination and the chemiluminescence method in the coagulation laboratory of the CCB MVZ laboratory. In addition, the platelet factor 4-induced platelet activation test (PIPA test) and the heparin-induced platelet activation test (HIPA test) as well as an ELISA-based platelet factor 4 IgG antibody test (Prof. Greinacher, Greifswald University Hospital) will be performed as part of the routine work up. In addition a new assay for heparin-independent anti-PF4 antibody detection provided by the company Werfen using chemiluminescence will be performed.
Locations (2)
Deutsches Herzzentrum der Charite (DHZC)
Berlin, Germany
Cardioangiologisches Zentrum Bethanien (CCB)
Frankfurt am Main, Germany